Attributes and levels tested
| Attributes | Levels |
| Disease-free/event-free survival | 12 months 18 months 24 months |
| Pathological complete response (pCR) | 30% probability of achieving pCR 50% probability of achieving pCR 70% probability of achieving pCR |
| Chances of undergoing breast-conserving surgery (BCS) after receiving anticancer treatment | 30% chance of undergoing BCS 50% chance of undergoing BCS 70% chance of undergoing BCS |
| Febrile neutropaenia | 5% risk of experiencing febrile neutropenia 10% risk of experiencing febrile neutropenia 20% risk of experiencing febrile neutropenia |
| Peripheral sensory neuropathy | 5% risk of experiencing peripheral sensory neuropathy 20% risk of experiencing peripheral sensory neuropathy 40% risk of experiencing peripheral sensory neuropathy |
| Diarrhoea | 10% risk of experiencing diarrhoea 25% risk of experiencing diarrhoea 50% risk of experiencing diarrhoea |
| Irreversible endocrine-related side effects requiring lifelong medication | 0% chance of developing irreversible endocrine-related side effects 8% chance of developing irreversible endocrine-related side effects |